

## Addendum to the Institutional License

This Addendum (hereinafter also referred to as "Addendum"), effective as of January 1<sup>st</sup> 2025, for the Subscription Period 2025, shall be attached to and made part of the Institutional License dated June 15<sup>th</sup> 2020, made by and between

**S. Karger AG**, Allschwilerstrasse 10, CH-4055 Basel, Switzerland  
(hereinafter referred to as the "**Licensor**" or "**Karger**")

and

**Universitat de Barcelona**, Gran Via de les Corts Catalanes, 585-08007, Barcelona, Spain  
(hereinafter referred to as "**Licensee**").

S. Karger AG and Universitat de Barcelona are hereinafter collectively referred to as "the Parties".

### Preamble

WHEREAS the Licensor desires to grant the Licensee and its Authorized Users the non-exclusive rights to access the Licensed Materials and to use the content for a further subscription period in accordance with the Terms & Conditions for the Use of Karger Online Publications by Institutional Users (Institutional License).  
The rights shall be granted against payment of a Publish and Access Fee.

WHEREAS the Licensee desires to gain the right to allow its Authorized Users to access and use the Licensed Materials for a further subscription period in accordance with the Terms & Conditions for the Use of Karger Online Publications by Institutional Users (Institutional License) by paying an appropriate Publish and Access Fee.

WHEREAS the Parties additionally agree that Eligible Authors shall be permitted to publish their accepted manuscripts in one of the Licensor's Eligible Journals according to the conditions of Schedule 1.

WHEREAS the Parties agree that the Terms & Conditions for the Use of Karger Online Publications by Institutional Users shall remain in force, as amended from time to time, except as explicitly stated otherwise in this Addendum.

This Addendum may be executed in counterparts, and signatures exchanged by electronic means (e.g., Adobe Sign) are effective to the same extent as original signatures.

## **A. Publishing Rights**

### **1. Definitions**

In this Addendum, the following terms shall have the following meanings:

- 1.1. **"Article Processing Charge"** means the charge made to, or any other fee payable by, the Licensee or Corresponding Authors at the Licensee in respect of publication of Open Access Articles in any of Licensors' Eligible Journals;
- 1.2. **"Corresponding Author"** shall mean the Licensors' main contact in connection with a submitted manuscript. The Corresponding Author might be listed as a single author or in addition to contributing co-authors in the manuscript;
- 1.3. **"Eligible Author"** shall mean either an individual employed for teaching and / or research purposes by Universitat de Barcelona, or a student enrolled at Universitat de Barcelona, who is also Corresponding Author and entitled to publish their manuscript in one of the Licensors' Eligible Journals;
- 1.4. **"Eligible Journals"** shall mean all Karger's Open Access and Hybrid Journals (subject to change by Licensors), with the exception of the journals in Karger's Partner Publication Portfolio and the Karger Kompass Series (marked with \* in Schedule 2). In case of titles being added to Karger's journal program (whether new or taken over from another publisher), Karger reserves the right to further exclude these titles from the list of "Eligible Journals";
- 1.5. **"Open Access Article"** means an article that is permanently, immediately free to read and re-use, published under an open license. Any article type published by the Licensors may be included.

### **2. Open Access Publishing**

- 2.1. Publication Rights apply based on an active arrangement for Licensors' eJournal Collection 2025.
- 2.2. Licensors grants Eligible Authors during the Subscription Period as specified in Schedule 1, non-exclusive, non-transferable publication rights to publish accepted articles as Open Access Articles in Licensors' Eligible Journals, without

incurring Article Processing Charge, provided that Corresponding Author submits material according to the workflow put forward by Licensor.

- 2.3. Eligible Authors retain copyright to their publications and only grant Licensor the non-exclusive right to publish all publications immediately and in the first instance under a Creative Commons Attribution license (CC BY 4.0). Third-party content included in a publication, for example images or graphics, should be clearly labelled and is not affected by these requirements. Nothing in this Addendum shall be taken to restrict, limit or curtail any provisions of the Creative Commons license used for Open Access Articles.
- 2.4. The provisions of this Addendum are without limitation to the rights of the Licensee or Authorized Users to do any act permitted under the Swiss copyright law, or permitted under any CC license applicable to the Licensed Materials or otherwise which, apart from the rights granted under this Addendum, would not infringe the intellectual property rights in the Licensed Materials and, notwithstanding any provision of this Addendum, the Licensee and Authorized Users shall remain entitled to do any such acts.

### 3. **Workflow**

- 3.1. Upon payment of the Publish and Access Fee, unlimited publishing rights will be available to Eligible Authors from the Licensee, for publication of articles in Licensor's Eligible Journals. The publishing rights are only valid for accepted research-oriented manuscripts and are applicable to Eligible Journals which require payment of an Article Processing Charge.
- 3.2. Eligibility must be claimed according to the workflow put forward by Licensor. Eligible Authors will indicate their entitlement to exemption from Article Processing Charges by specifying their affiliated institute in the course of the manuscript submission process.


### 4. **Editorial Independence**


- 4.1. Licensor and Licensee recognize that Licensee will not be involved in the editorial processes governing the publication of Open Access Articles despite the financial obligations towards the Licensor.
- 4.2. Nothing herein contained shall oblige the Licensor or any third party to accept or publish any article submitted to the Licensor by an Eligible Author. Licensee acknowledges that the selection of material to be accepted and published by the Licensor or a third party in control of the publishing process is entirely at the

discretion of the Licensor or said third party. Licensee waives any claim they may have against the Licensor or said third party in the event that the Licensor or said third party refuses or declines to publish any material (or part thereof) submitted by an Eligible Author.

**Licensor:**

**S.Karger AG**

  
Christian Box (Feb 13, 2025 09:29 GMT)

  
Thomas Kugler (Feb 11, 2025 09:49 GMT+1)

Christian Box,

Thomas Kugler,

Head of Academic and Research Markets


Head of Front Office

Date: 13/02/2025

Date: 11/02/2025

**Licensee:**

**Universitat de Barcelona**

  
Judit Casals Parladé (Feb 11, 2025 20:21 GMT+1)

Judit Casals Parladé,

Director of the CRAI of the University of

Barcelona

Date: 11/02/2025

### **Schedule 1: Business Terms and Fees**

#### **1. Materials and Services - Subscribed Content**

**Karger eJournal complete Collection 2025:** Access to all Karger eJournals 2025

Subscription Period: January 1<sup>st</sup>, 2025, to December 31<sup>st</sup>, 2025

#### **2. Publish and Access Fee(s)**

	<b>2025</b>
Publish and Access Fee	EUR 65'850.00

Invoice payable in EUR via Ebsco within thirty (30) days of invoice date.

## Schedule 2: Licensed Materials

### 1. Subscription Journals 2025

Title	eISSN	URL
Acta Cytologica	1938–2650	<a href="http://www.karger.com/ACY">www.karger.com/ACY</a>
Acta Haematologica	1421–9662	<a href="http://www.karger.com/AHA">www.karger.com/AHA</a>
American Journal of Nephrology	1421–9670	<a href="http://www.karger.com/AJN">www.karger.com/AJN</a>
Annals of Nutrition and Metabolism	1421–9697	<a href="http://www.karger.com/ANM">www.karger.com/ANM</a>
Audiology and Neurotology	1421–9700	<a href="http://www.karger.com/AUD">www.karger.com/AUD</a>
Blood Purification	1421–9735	<a href="http://www.karger.com/BPU">www.karger.com/BPU</a>
Brain, Behavior and Evolution	1421–9743	<a href="http://www.karger.com/BBE">www.karger.com/BBE</a>
Breast Care	1661–3805	<a href="http://www.karger.com/BRC">www.karger.com/BRC</a>
Cardiology	1421–9751	<a href="http://www.karger.com/CRD">www.karger.com/CRD</a>
Caries Research	1421–976X	<a href="http://www.karger.com/CRE">www.karger.com/CRE</a>
Cells Tissues Organs	1422–6421	<a href="http://www.karger.com/CTO">www.karger.com/CTO</a>
Cerebrovascular Diseases	1421–9786	<a href="http://www.karger.com/CED">www.karger.com/CED</a>
Chemotherapy	1421–9794	<a href="http://www.karger.com/CHE">www.karger.com/CHE</a>
Complementary Medicine Research	2504–2106	<a href="http://www.karger.com/CMR">www.karger.com/CMR</a>
Complex Psychiatry	2673–298X	<a href="http://www.karger.com/CXP">www.karger.com/CXP</a>
Cytogenetic and Genome Research	1424–859X	<a href="http://www.karger.com/CGR">www.karger.com/CGR</a>
Dementia and Geriatric Cognitive Disorders	1421–9824	<a href="http://www.karger.com/DEM">www.karger.com/DEM</a>
Dermatology	1421–9832	<a href="http://www.karger.com/DRM">www.karger.com/DRM</a>
Developmental Neuroscience - <b>Subscribe2Open</b>	1421–9859	<a href="http://www.karger.com/DNE">www.karger.com/DNE</a>
Digestion	1421–9867	<a href="http://www.karger.com/DIG">www.karger.com/DIG</a>
Digestive Diseases	1421–9875	<a href="http://www.karger.com/DDI">www.karger.com/DDI</a>
Digestive Surgery	1421–9883	<a href="http://www.karger.com/DSU">www.karger.com/DSU</a>
European Addiction Research - <b>Subscribe2Open</b>	1421–9891	<a href="http://www.karger.com/EAR">www.karger.com/EAR</a>
European Neurology	1421–9913	<a href="http://www.karger.com/ENE">www.karger.com/ENE</a>
Fetal Diagnosis and Therapy	1421–9964	<a href="http://www.karger.com/FDT">www.karger.com/FDT</a>
Folia Phoniatica et Logopaedica	1421–9972	<a href="http://www.karger.com/FPL">www.karger.com/FPL</a>
Gerontology	1423–0003	<a href="http://www.karger.com/GER">www.karger.com/GER</a>
Gynecologic and Obstetric Investigation	1423–002X	<a href="http://www.karger.com/GOI">www.karger.com/GOI</a>
Hormone Research in Paediatrics	1663–2826	<a href="http://www.karger.com/HRP">www.karger.com/HRP</a>
Human Development	1423–0054	<a href="http://www.karger.com/HDE">www.karger.com/HDE</a>
International Archives of Allergy and Immunology	1423–0097	<a href="http://www.karger.com/IAA">www.karger.com/IAA</a>
Journal of Vascular Research	1423–0135	<a href="http://www.karger.com/JVR">www.karger.com/JVR</a>
Molecular Syndromology	1661–8777	<a href="http://www.karger.com/MSY">www.karger.com/MSY</a>
Neonatology	1661–7819	<a href="http://www.karger.com/NEO">www.karger.com/NEO</a>
Nephron	2235–3186	<a href="http://www.karger.com/NEF">www.karger.com/NEF</a>
Neurodegenerative Diseases - <b>Subscribe2Open</b>	1660–2862	<a href="http://www.karger.com/NDD">www.karger.com/NDD</a>

Neuroendocrinology	1423-0194	<a href="http://www.karger.com/NEN">www.karger.com/NEN</a>
Neuroepidemiology	1423-0208	<a href="http://www.karger.com/NED">www.karger.com/NED</a>
Neuropsychobiology	1423-0224	<a href="http://www.karger.com/NPS">www.karger.com/NPS</a>
Ocular Oncology and Pathology	2296-4657	<a href="http://www.karger.com/OOP">www.karger.com/OOP</a>
Oncology	1423-0232	<a href="http://www.karger.com/OCL">www.karger.com/OCL</a>
Oncology Research and Treatment	2296-5262	<a href="http://www.karger.com/ORT">www.karger.com/ORT</a>
Ophthalmologica	1423-0267	<a href="http://www.karger.com/OPH">www.karger.com/OPH</a>
ORL	1423-0275	<a href="http://www.karger.com/ORL">www.karger.com/ORL</a>
Pathobiology	1423-0291	<a href="http://www.karger.com/PAT">www.karger.com/PAT</a>
Pediatric Neurosurgery - <b>Subscribe2Open</b>	1423-0305	<a href="http://www.karger.com/PNE">www.karger.com/PNE</a>
Pharmacology	1423-0313	<a href="http://www.karger.com/PHA">www.karger.com/PHA</a>
Psychopathology	1423-033X	<a href="http://www.karger.com/PSP">www.karger.com/PSP</a>
Psychotherapy and Psychosomatics	1423-0348	<a href="http://www.karger.com/PPS">www.karger.com/PPS</a>
Respiration	1423-0356	<a href="http://www.karger.com/RES">www.karger.com/RES</a>
Sexual Development	1661-5433	<a href="http://www.karger.com/SXD">www.karger.com/SXD</a>
Skin Appendage Disorders	2296-9160	<a href="http://www.karger.com/SAD">www.karger.com/SAD</a>
Skin Pharmacology and Physiology	1660-5535	<a href="http://www.karger.com/SPP">www.karger.com/SPP</a>
Stereotactic and Functional Neurosurgery	1423-0372	<a href="http://www.karger.com/SFN">www.karger.com/SFN</a>
Urologia Internationalis	1423-0399	<a href="http://www.karger.com/UIN">www.karger.com/UIN</a>
Verhaltenstherapie	1423-0402	<a href="http://www.karger.com/VER">www.karger.com/VER</a>
Visceral Medicine	2297-475X	<a href="http://www.karger.com/VIS">www.karger.com/VIS</a>

## 2. Open Access Journals 2025

Title	eISSN	URL
Biomedicine Hub	2296-6870	<a href="http://www.karger.com/BMH">www.karger.com/BMH</a>
Cardiorenal Medicine	1664-5502	<a href="http://www.karger.com/CRM">www.karger.com/CRM</a>
Case Reports in Dermatology	1662-6567	<a href="http://www.karger.com/CDE">www.karger.com/CDE</a>
Case Reports in Gastroenterology	1662-0631	<a href="http://www.karger.com/CRG">www.karger.com/CRG</a>
Case Reports in Nephrology and Dialysis	2296-9705	<a href="http://www.karger.com/CND">www.karger.com/CND</a>
Case Reports in Neurology	1662-680X	<a href="http://www.karger.com/CRN">www.karger.com/CRN</a>
Case Reports in Oncology	1662-6575	<a href="http://www.karger.com/CRO">www.karger.com/CRO</a>
Case Reports in Ophthalmology	1663-2699	<a href="http://www.karger.com/COP">www.karger.com/COP</a>
Cerebrovascular Diseases Extra	1664-5456	<a href="http://www.karger.com/CEE">www.karger.com/CEE</a>
Dementia and Geriatric Cognitive Disorders Extra	1664-5464	<a href="http://www.karger.com/DEE">www.karger.com/DEE</a>
Digital Biomarkers	2504-110X	<a href="http://www.karger.com/DIB">www.karger.com/DIB</a>
Endocrinology Insights	2813-9151	<a href="http://www.karger.com/ENI">www.karger.com/ENI</a>
European Surgical Research	1421-9921	<a href="http://www.karger.com/ESR">www.karger.com/ESR</a>
GE - Portuguese Journal of Gastroenterology*	2387-1954	<a href="http://www.karger.com/PJG">www.karger.com/PJG</a>
Glomerular Diseases	2673-3633	<a href="http://www.karger.com/GDZ">www.karger.com/GDZ</a>
Human Heredity	1423-0062	<a href="http://www.karger.com/HHE">www.karger.com/HHE</a>

Immune System	2813-0073	<a href="http://www.karger.com/IMS">www.karger.com/IMS</a>
Inflammatory Intestinal Diseases	2296-9365	<a href="http://www.karger.com/IID">www.karger.com/IID</a>
Intervirology	1423-0100	<a href="http://www.karger.com/INT">www.karger.com/INT</a>
Journal of Innate Immunity	1662-8128	<a href="http://www.karger.com/JIN">www.karger.com/JIN</a>
Kidney and Blood Pressure Research	1423-0143	<a href="http://www.karger.com/KBR">www.karger.com/KBR</a>
Kidney Diseases	2296-9357	<a href="http://www.karger.com/KDD">www.karger.com/KDD</a>
Lifestyle Genomics	2504-3188	<a href="http://www.karger.com/LFG">www.karger.com/LFG</a>
Liver Cancer	1664-5553	<a href="http://www.karger.com/LIC">www.karger.com/LIC</a>
Maternal and Children's Health	2813-8996	<a href="http://www.karger.com/MCH">www.karger.com/MCH</a>
Medical Cannabis and Cannabinoids	2504-3889	<a href="http://www.karger.com/MCA">www.karger.com/MCA</a>
Medical Principles and Practice*	1423-0151	<a href="http://www.karger.com/MPP">www.karger.com/MPP</a>
Microbial Physiology	2673-1673	<a href="http://www.karger.com/MIP">www.karger.com/MIP</a>
Neuroimmunomodulation	1423-0216	<a href="http://www.karger.com/NIM">www.karger.com/NIM</a>
Obesity Facts	1662-4033	<a href="http://www.karger.com/OFA">www.karger.com/OFA</a>
Ophthalmic Research	1423-0259	<a href="http://www.karger.com/ORE">www.karger.com/ORE</a>
Portuguese Journal of Public Health*	2504-3145	<a href="http://www.karger.com/PJP">www.karger.com/PJP</a>
Public Health Genomics	1662-8063	<a href="http://www.karger.com/PHG">www.karger.com/PHG</a>
Pulse	2235-8668	<a href="http://www.karger.com/PLS">www.karger.com/PLS</a>
Saudi Journal of Health Systems Research*	2673-6136	<a href="http://www.karger.com/SJH">www.karger.com/SJH</a>
Transfusion Medicine and Hemotherapy	1660-3818	<a href="http://www.karger.com/TMH">www.karger.com/TMH</a>

### 3. Free Access Journals 2025

Title	eISSN	URL
*Kompass Autoimmun	2624-8476	<a href="http://www.karger.com/KAI">www.karger.com/KAI</a>
*Kompass Dermatologie	2296-536X	<a href="http://www.karger.com/KKD">www.karger.com/KKD</a>
*Kompass Nutrition & Dietetics	2673-5199	<a href="http://www.karger.com/KND">www.karger.com/KND</a>
*Kompass Onkologie	2296-5386	<a href="http://www.karger.com/KKO">www.karger.com/KKO</a>
*Kompass Ophthalmologie	2297-0045	<a href="http://www.karger.com/KOP">www.karger.com/KOP</a>
*Kompass Pneumologie	2296-0317	<a href="http://www.karger.com/KKP">www.karger.com/KKP</a>




# Publish Access Amendment\_Univ of Barcelona\_2025

Final Audit Report

2025-02-13

Created:	2025-02-10
By:	Veronika Duhovnikova (v.duhovnikova@karger.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAmg4qlwWJ6F51QV4VIXQfCaLwVY--mqeh

## "Publish Access Amendment\_Univ of Barcelona\_2025" History

 Document created by Veronika Duhovnikova (v.duhovnikova@karger.com)

2025-02-10 - 6:32:10 PM GMT

 Document emailed to Christian Box (c.box@karger.com) for signature

2025-02-10 - 6:32:15 PM GMT

 Document emailed to Thomas Kugler (t.kugler@karger.com) for signature

2025-02-10 - 6:32:15 PM GMT

 Document emailed to Judit Casals Parladé (revistes@ub.edu) for signature

2025-02-10 - 6:32:15 PM GMT

 Email viewed by Judit Casals Parladé (revistes@ub.edu)

2025-02-11 - 8:05:09 AM GMT

 Email viewed by Thomas Kugler (t.kugler@karger.com)

2025-02-11 - 8:49:05 AM GMT

 Document e-signed by Thomas Kugler (t.kugler@karger.com)

Signature Date: 2025-02-11 - 8:49:21 AM GMT - Time Source: server

 Document e-signed by Judit Casals Parladé (revistes@ub.edu)

Signature Date: 2025-02-11 - 7:21:03 PM GMT - Time Source: server

 Email viewed by Christian Box (c.box@karger.com)

2025-02-13 - 9:29:17 AM GMT

 Document e-signed by Christian Box (c.box@karger.com)

Signature Date: 2025-02-13 - 9:29:38 AM GMT - Time Source: server

✔ Agreement completed.

2025-02-13 - 9:29:38 AM GMT